Introduction
============

Atherosclerosis is considered to be a chronic inflammatory disease and plays a key role in heart attacks, strokes, and peripheral vascular diseases ([@B24]; [@B13]). Over the last decades, atherosclerotic cardiovascular diseases remain the leading cause of mortality worldwide ([@B14]). One critical event in the initiation of atherosclerosis is the ox-LDL uptake, which contributes to the atherosclerotic foam cell and plaque formation ([@B41]; [@B20]). Ox-LDL uptake is principally mediated by a variety of specific receptors including SR-A I/II, CD36, SR-BI, etc. ([@B22]; [@B19]). Recently, LOX-1 has been identified as the main endothelial receptor for ox-LDL ([@B39]; [@B5]). LOX-1 is a 50-kD transmembrane protein highly expressed on macrophages, vascular smooth muscle cells, and especially endothelial cells, which plays important roles in the pathogenesis of diabetic cardiovascular complications, myocardial ischemia, and atherosclerosis ([@B27]; [@B49]; [@B48]). Disturbance of LOX-1 mediated signaling pathways has been proposed as a potential strategy for the anti-atherosclerotic drug discovery ([@B39]; [@B5], [@B9]). Although a variety of cells, including monocytes, dendritic cells, lymphocytes, eosinophils, mast cells and smooth muscle cells, contribute to atherogenesis ([@B32]), endothelial dysfunction is considered to be an early marker and played important roles in the pathophysiology of atherosclerosis ([@B10]). ROS, an important second messenger, is linked to many vascular diseases including atherosclerosis ([@B44]). NOX4 is an important source of ROS in endothelial cells ([@B38]). However, the role of NOX4 in atherosclerosis is controversial ([@B18]; [@B53]). Furthermore, the TLRs-NF-κB pathway has been reported to participate in the anti-atherosclerotic effect of several natural products such as quercetin, pycnogenol, and procyanidins ([@B29]; [@B28]; [@B2]).

*Salvia miltiorrhiza* Bunge (Danshen) is a famous medical herb with a long history of clinical application for treating cardiovascular diseases, cancer, and osteoporosis ([@B4]; [@B8]; [@B16]). Its ingredients have been widely explored since last century. Two groups of ingredients, the hydrophilic phenolic acids and the lipophilic tanshinones, have been identified as the main bioactive components. Tanshinones are a group of abietane diterpenes composed of four rings. Totally, more than 50 tanshinones have been isolated and identified since 1934 ([@B12]). However, only a few of them, such as tanshinone IIA ([@B47]) and cryptotanshinone ([@B6]), have been widely investigated. DHT (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}), a tanshinone isolated from Danshen, is structurally similar to that of tanshinone IIA and cryptotanshinone. For a long time, investigation to its bioactivities was mainly focused on its cytotoxicity to a variety of tumor cells ([@B26]; [@B45]). Although increasing evidence suggested that DHT has beneficial potentials for the treatment of cardiovascular diseases ([@B51]; [@B25]), its anti-atherosclerotic effect, either *in vivo* or *in vitro*, has not been fully established. Here, this effect was evaluated with experimental atherosclerosis model in ApoE^-/-^ mice and HUVECs. Furthermore, the underlying mechanisms were explored as well.

Materials and Methods {#s1}
=====================

Materials
---------

DHT (purity ≥ 98% by HPLC analysis, a lipophilic diterpenes) was purchased from Chengdu Herbpurify Co. Ltd. (Chendu, China). Hoechst 33342, *N*-acetyl cysteine (NAC), DPI, Rot, TTFA, AA, All, NDGA, LPS (*Escherichia coli* serotype 055:B5, LPS), 5-(6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (DCFH~2~-DA), PDTC, 2,2-Diphenyl-1-picrylhydrazyl (DPPH) and lucigenin were purchased from Sigma--Aldrich (St. Louis, MO, USA). Lipofectamine TM2000, DHE and Amplex Red were purchased from Life Technology (Grand Island, NY, USA). Antibodies for NOX4, p22-phox, TLR4, MyD88 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies for NF-κB p65, GAPDH, and Histone H3 were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-LOX-1 antibody was obtained from R&D (Minneapolis, MN, USA). The BCA protein kits were purchased from Thermo Fisher (Suwanee, GA, USA). Fraction-PREP Cell Fractionation Kit was purchased from BioVision (Milpitas, CA, USA). SiRNA for TLR4, MyD88, and NOX4 were purchased from Gene Pharma Company (Shanghai, China). Primers and other materials for real-time PCR were purchased from Sangon Biotech (Haimen, China) and TaKaRa Bio Group (Shiga, Japan). DiI-ox-LDL was purchased from Yiyuan Biotechnology (Guangzhou, China).

Kits for TC, LDL-C, HDL-C, TG, MDA, GSH, and SOD were obtained from Nanjing Jiancheng Bioengineering Research Institute (Nanjing, China).

Cell Culture
------------

Human umbilical vein endothelial cells were cultured in Vascular Cell Basal Medium with Endothelial Cell Growth Kit-BBE at 37°C in a humidified atmosphere of 5% CO~2~. Before passaging cells, issue culture flasks, 96-well plates and 6-well plates were pre-coated with 0.1% gelatin. All assays were conducted using low cell passage cells (2--5 passages).

Human monocyte cell line (THP-1) obtained from ATCC (no: TIB-202, Rockville, MA, USA) was cultured in RPMI 1640 medium containing 10% fetal calf serum, 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells were seeded at 37°C in a humidified atmosphere of 5% CO~2~ and 95% air.

Animal Experiment
-----------------

Male ApoE^-/-^ mice (6--8 weeks old) on C57BL/6J background and age-matched wild-type C57BL/6J controls were purchased from Beijing HFK Bioscience Co., Ltd. (Beijing, China). Mice were housed in SPF-grade animal facilities (Certificate no. SCXK 2014-0004) at Zunyi Medical College, with a 12 h light/dark cycle, at 23°C (±2°C). All animal procedures follow the NIH guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1978), and approved by the Institutional Animal Use and Care Committee of Zunyi Medical College. Starting from 6 weeks, the mice were fed with a HCD (54.35% raw grain, 20% lard, 0.15% cholesterol, 15% sucrose, 0.5% Sodium Cholate, 10% yolk powder) for 12 weeks. All ApoE^-/-^ mice were dosed daily *via* intragastric gavage with 10 and 25 mg kg^-1^ DHT dissolved in 0.5% CMC-Na or administered 0.5% CMC-Na alone (vehicle control) (*n* = 8 per group).

Immunofluorescence Assay
------------------------

Cells (1 × 10^4^ cells/well) were seeded on glass slides in 96-well plates. After LPS treatment (Sigma--Aldrich, St. Louis, MO, USA) (with or without DHT pretreatment), the slides were fixed with 4% PFA for 30 min. Then the slides were permeabilized with PBS-T (containing 0.1% Triton x-100 in PBS solution) and blocked with PBS-B (containing 4% BSA in PBS solution). After incubated with primary antibody (1:1000) and secondary antibody (1:2000), cells were stained with Hoechst 33342 in dark for 5 min. The protein location and expression were observed with IN Cell Analyzer 2000 (GE Healthcare).

Detection of Reactive Oxygen Species, Superoxide Anion ($O_{2}^{\bullet-}$), and Hydrogen Peroxide (H~2~O~2~)
-------------------------------------------------------------------------------------------------------------

The effect of DHT on LPS-induced $O_{2}^{\bullet-}$, H~2~O~2~, and ROS production were measured by DHE, Amplex Red, and DCFH~2~-DA, respectively. Briefly, after LPS treatment for 30 min, cells were washed with PBS and incubated with DHE (10 μM), Amplex Red (50 μM), or DCFH~2~-DA (10 μM) for 30 min in the dark at 37°C. Then, cells were washed with PBS for three times and fluorescence density was measured by Spectra Max M5 Microplate Reader (Molecular Devices, Sunnyvale, CA, USA) or by a flow cytometry using a FACSCantoTM system (BD Biosciences).

DPPH Assay
----------

To evaluate the direct scavenging effect of DHT on free radicals in cell-free system, the DPPH system was adapted. DHT (0.01--1 μM, final concentration) was incubated with ethanol solution of DPPH (5.0 × 10^-4^ M). After thoroughly mixing, the solutions were kept in the dark for 20 min and the absorbency was measured at 517 nm.

Western Blotting
----------------

Treated HUVECs were washed twice with ice-cold PBS and lysed with RIPA buffer supplemented with a protease cocktail and phosphatase inhibitors. The cell lysates were separated using 8--12% SDS-PAGE and transferred onto PVDF membranes. After blocked with 5% non-fat milk in TBST (20 mM Tris-HCl, 500 mM NaCl, and 0.1% Tween 20) at room temperature for 1 h, membranes were incubated with specific primary antibodies and secondary antibodies. The protein-antibody complexes were detected by ECL Advanced Western Blot detection Kit. The intensity of the band was quantitated with Quantity One software (Bio-Rad).

Preparation of Membrane, Cytoplasmic and Nuclear Fractions
----------------------------------------------------------

The cytoplasmic and membrane proteins were isolated using Fraction-PREP cell fractionation kit (Biovision Inc., Milpitas, CA, USA) according to the manufacturer's instructions^[1](#fn01){ref-type="fn"}^.

SiRNA Transfection
------------------

Gene silencing experiment of TLR4, MyD88, and NOX4 with siRNA was performed according to our previous report ([@B53]).

Real-Time RT-PCR
----------------

The mRNA expression of LOX-1 was determined with real-time PCR as our previous report ([@B53]).

DiI-ox-LDL Uptake
-----------------

The DiI-ox-LDL uptake assay was performed according to our previous study with minor revisions ([@B52]). Cells (1.0 × 10^4^/well) in 96-well plate cultured for overnight were pretreated with DHT, inhibitors, or anti-LOX-1 antibody for 1 h and then co-treated with LPS for another 24 h. After incubated with DiI-ox-LDL (1 μg/mL) for 1 h at 37°C in the dark, the cells were gently washed with PBS for three times to remove the free DiI-ox-LDL and the ox-LDL uptake was measured with IN Cell Analyzer 2000.

Monocyte-endothelial Cell Adhesion Assay
----------------------------------------

After various treatments, HUVECs were co-incubated with THP-1 cells labeled with Hoechst 33342 for 3 h in the dark at 37°C. The non-adherent THP-1 cells were washed gently with PBS. Images were obtained under random fields of each well using IN Cell Analyzer 2000.

Immunohistochemistry
--------------------

Immunohistochemical analysis on aortic sinus was performed as described previously in detail ([@B46]). Sections, 8 μm thick, were used for immunohistochemical staining with LOX-1, NOX4 and phosphorylated NF-κB p65 antibodies. Color reaction was developed with diaminobenzidine.

Aorta Collection and Lesion Size Evaluation
-------------------------------------------

To evaluate plaque extension, frozen sections of the aortic sinus (8 μm) were stained using Oil Red O, hematoxylin and eosin (H&E), respectively. Related experiments were performed following the method of [@B33].

Blood Parameters
----------------

Blood samples were collected from the orbit before the mice were killed. Serum TC, LDL-C, HDL-C, and TG were measured using standard enzymatic colorimetric assays. MDA, GSH, and SOD were detected by commercial kits.

Statistical Analysis
--------------------

Twenty four ApoE^-/-^ mice were randomly allocated to groups and equal group sizes were obtained (*n* = 8 per group). Data were expressed as the means ± SD. The differences between groups were analyzed using Prism 5.0 (Graph Pad Software Inc, San Diego, CA, USA) and the statistical analysis was performed by analysis of variance (one-way ANOVA) followed by Student Newman--Keuls test. *p* \< 0.05 is considered statistically significant.

Results
=======

DHT Inhibited LPS-Induced LOX-1 Expression
------------------------------------------

Firstly, the cytotoxic effect of DHT on HUVECs was determined by MTT assay. Results showed that DHT was cytotoxic to HUVECs at 1 μM (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). To minimize the cytotoxic effect of DHT on cell viability, 10 nM DHT was chosen for further study. Compared with untreated HUVECs, 24 h stimulation with LPS induced significant LOX-1 expression at both mRNA (**Figure [1A](#F1){ref-type="fig"}**) and protein (**Figure [1B](#F1){ref-type="fig"}**) levels, which were dramatically inhibited by DHT pretreatment. Furthermore, immunofluorescence results showed that LPS-induced LOX-1 expression was mainly localized on the membrane, which was significantly suppressed by DHT as well (**Figure [1C](#F1){ref-type="fig"}**).

![**DHT inhibited LPS-induced LOX-1 expression.** Cells were pretreated with DHT (10 nM) for 1 h and then stimulated with LPS (5 μg/mL) for 24 h, the LOX-1 mRNA **(A)**, protein **(B)**, and localization **(C)** were detected by real-time PCR, western blotting and immunofluorescence (60×), respectively. DHT, dihydrotanshinone I.](fphar-07-00418-g001){#F1}

DHT Inhibited LPS-Induced LOX-1 Expression via TLR4/Myd88
---------------------------------------------------------

Our previous study demonstrated that TLR4/MyD88 signal pathway was involved in LPS-induced LOX-1 expression in endothelial cells ([@B53]). Here, LPS-induced expression of TLR4 and MyD88 was obviously inhibited by DHT (**Figure [2A](#F2){ref-type="fig"}**). Furthermore, silence of either TLR4 or MyD88 did not affect the expression of LOX-1 in the absence of LPS (**Figures [2B--D](#F2){ref-type="fig"}**). In addition, the LPS-induced expression of LOX-1 was significantly decreased in both TLR4 and MyD88 silenced cells (**Figure [2E](#F2){ref-type="fig"}**).

![**DHT inhibited LPS-induced LOX-1 expression *via* TLR4/MyD88.** Cells were pretreated with DHT (10 nM) for 1 h and then stimulated by LPS (5 μg/mL) for 24 h, expressions of TLR2, TLR4 and MyD88 were determined by western blotting **(A)**. Cells were transfected with siRNAs for TLR4 **(B)** and MyD88 **(C)** and then stimulated with LPS (5 μg/mL) for 24 h and the LOX-1 expression were determined by western blotting **(D,E)**. Cont, control; NC-siRNA, negative control siRNA. DHT, dihydrotanshinone I; N.S, no significant differences.](fphar-07-00418-g002){#F2}

DHT Inhibited LPS-Induced ROS Generation
----------------------------------------

LOX-1 was reported to be upregulated by oxidative stress in vascular smooth muscle cells ([@B42]) and endothelial cells ([@B53]). LPS treatment for 4 h induced endothelial ROS generation as detected by DCFH~2~-DA (**Figure [3A](#F3){ref-type="fig"}**). Amplex Red and DHE assay showed that the generation of both H~2~O~2~ and $O_{2}^{\bullet-}$ was also significantly increased after LPS stimulation. DHT and NAC pretreatment dramatically inhibited these increases (**Figures [3B,C](#F3){ref-type="fig"}**). However, no effect of DHT on DPPH was observed (**Figure [3D](#F3){ref-type="fig"}**).

![**DHT inhibited LPS-induced ROS, H~2~O~2~, and $O_{2}^{\bullet-}$ production.** ROS **(A)**, H~2~O~2~ **(B)**, and **$O_{2}^{\bullet-}$ (C)** production were determined by DCFH~2~-DA, Amplex Red and DHE respectively, after LPS (5 μg/mL) treatment for 1 h with or without DHT (10 nM) or NAC (5 mM) pretreatment for 1 h. Effect of DHT on DPPH radical was determined in a cell-free system **(D)**. DHT, dihydrotanshinone I; ROS, reactive oxygen species; NAC, *N*-acetyl cysteine.](fphar-07-00418-g003){#F3}

DHT Inhibited LPS-Induced LOX-1 Expression Through NOX4
-------------------------------------------------------

LPS-induced ROS generation was significantly inhibited by DPI while NDGA, allopurinol (All), Rot, TTFA, and AA showed no obvious effect (**Figure [4A](#F4){ref-type="fig"}**). Furthermore, LPS increased NOX4 protein expression (**Figure [4B](#F4){ref-type="fig"}**) and membrane aggregation (**Figure [4C](#F4){ref-type="fig"}**) which was also inhibited by DHT. LPS-induced p22phox expression was suppressed by DHT (**Figure [4D](#F4){ref-type="fig"}**). In addition, silence NOX4 (**Figure [4E](#F4){ref-type="fig"}**) dramatically inhibited LPS-induced LOX-1 expression (**Figure [4F](#F4){ref-type="fig"}**) (Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}).

![**DHT inhibited LPS-induced NOX4 dependent ROS generation.** Cells were treated with LPS (5 μg/mL) with or without 1 h pretreatment with DPI (1 μM), NDGA (10 μM), All (10 μM), Rot (20 μM), TTFA (10 μM) or AA (5 μM) and the ROS was determined **(A)**. NOX4 expression and localization were determined by western blotting **(B)** and immunofluorescence **(C)** (60×). P22phox expression was determined by western blotting **(D)**. Cells were transfected with NOX4 siRNA, NOX4 **(E)** and LOX-1 expression **(F)** were determined by western blotting. Cont, control group; DHT, dihydrotanshinone I; NC-siRNA, negative control siRNA; DPI, diphenyleneiodonium chloride; NDGA, nordihydroguaiaretic acid; All, allopurinol; AA, antimycin A; Rot, rotenone; TTFA, 2-thenoyltrifluoroacetone.](fphar-07-00418-g004){#F4}

DHT Inhibited LPS-Induced LOX-1 Expression by Suppressing NF-κB Activation
--------------------------------------------------------------------------

NF-κB pathway plays an essential role in LPS-induced LOX-1 expression in HUVECs ([@B53]). The NF-κB p65 in the nuclear in response to LPS was significantly increased which was remarkably suppressed by DHT treatment (**Figure [5A](#F5){ref-type="fig"}**). Furthermore, LPS-induced LOX-1 expression was inhibited by PDTC, a NF-κB inhibitor (**Figure [5B](#F5){ref-type="fig"}**). In addition, LPS-induced p65 nuclear translocation was significantly suppressed by NOX4 siRNA (**Figure [5C](#F5){ref-type="fig"}**).

![**DHT inhibited LPS-induced LOX-1 expression *via* NF-κB.** Cells were treated with LPS (5 μg/mL) for 24 h with or without pretreatment with DHT, PDTC, or NOX4 siRNA and the expression of p65 **(A)**, LOX-1 **(B)**, and p65 **(C)** was detected by western blotting. DHT, dihydrotanshinone I; PDTC, pyrrolidine dithiocarbamic acid.](fphar-07-00418-g005){#F5}

DHT Inhibited LPS-Induced Ox-LDL Uptake Mediated by LOX-1
---------------------------------------------------------

In the DiI-ox-LDL uptake assay, compared with untreated cells, LPS stimulation resulted in increased intracellular red fluorescence in stimulated endothelial cells suggesting the increase of DiI-ox-LDL internalization (**Figure [6A](#F6){ref-type="fig"}**). This increase was significantly reversed by pretreatment with DHT, NOX4 siRNA, PDTC, and anti-LOX-1 antibody.

![**DHT inhibited LPS-induced ox-LDL uptake and monocyte adhesion mediated by LOX-1.** Cells were pretreated with DHT (10 nM), siNOX4, PDTC (10 μM), or anti-LOX-1 Ab (10 μg/mL) for 1 h before LPS treatment for 24 h. Then cells were incubated with DiI-ox-LDL (5 μg/mL) and the ox-LDL uptake was measured with an inverted fluorescent microscopy (20×) **(A)**. Cells received same treatment and were co-incubated with Hoechst 33342 labeled THP-1 cells. The attached THP-1 cells were visualized by an inverted fluorescent microscopy (20×) **(B)**. DHT, dihydrotanshinone I; NC-siRNA, negative control siRNA; PDTC, pyrrolidine dithiocarbamic acid.](fphar-07-00418-g006){#F6}

DHT Inhibited LPS-Induced THP-1 Adhesion Mediated by LOX-1
----------------------------------------------------------

We previously reported the potential role of LOX-1 in LPS-mediated monocyte-endothelial cells adhesion ([@B53]). In present research, LPS treatment for 24 h significantly increased THP-1 cell adhesion to endothelial cells, which was also dramatically inhibited by DHT, NOX4 siRNA, PDTC, and anti-LOX-1 antibody (**Figure [6B](#F6){ref-type="fig"}**).

DHT Ameliorated the Serum Lipid Profile in ApoE^-/-^ Mice
---------------------------------------------------------

As shown in **Figures [7A--C](#F7){ref-type="fig"}**, compared with the WT mice, high-fat diet induced dramatically increase in TG, TC, LDL-C, as well as HDL-C in ApoE^-/-^ mice. Low dosage of DHT mildly decreased the lipid levels of TC and LDL-C but showed no effect on TG while at high dosage DHT dramatically inhibited TG, TC, and LDL-C. Both dosages of DHT showed no effect on HDL-C (**Figure [7D](#F7){ref-type="fig"}**).

![**DHT ameliorated serum lipid profile and reduced atherosclerosis in ApoE^-/-^ mice.** The serum TG, TC, LDL-C, and HDL-C were measured by colorimetric assays **(A--D)**. Aortic sinus sections were stained with Oil Red O and H&E to detect plaque sizes **(E)** (40×) and necrotic core areas **(F)** respectively (40×). DHT, dihydrotanshinone I; TC, total cholesterol; TG, triglycerides; LDL-C, LDL cholesterol; HDL-C, HDL- cholesterol; Nec, necrotic core area; WT, wild type; ApoE^-/-^, apolipoprotein E-deficient; N.S, no significant differences.](fphar-07-00418-g007){#F7}

DHT Reduced Atherosclerotic Plaque Development in ApoE^-/-^ Mice
----------------------------------------------------------------

Histopathological studies had showed that an atherosclerotic plaques (Oil red O-stained red area) was formed and obvious necrotic core areas (H&E-stained area) were observed in ApoE^-/-^ mice. DHT administration significantly reduced plaque sizes as well as shrank necrotic core areas. High dosage showed more potent inhibitory effect (**Figures [7E,F](#F7){ref-type="fig"}**).

DHT Reduced Oxidative Stress in ApoE^-/-^ Mice
----------------------------------------------

As shown in **Figures [8C--E](#F8){ref-type="fig"}**, there was a slight decrease of SOD while nearly fivefolds decrease of GSH and twofolds increase of MDA in ApoE^-/-^ mice compared to WT mice. The decreased SOD and GSH and the increased MDA levels in the serum were significantly reversed by DHT administration.

![**DHT reduced oxidative stress, inhibited LOX-1, NF-κB, and LOX-1 expression in ApoE^-/-^ mice.** Expression of LOX-1 **(A)**, NOX4 **(F)**, and NF-κB p65 **(G)** in the aorta was detected by immunohistochemistry. The MDA, GSH and SOD levels were detected by kits **(C--E)**. LOX-1 expression was detected by immunofluorescence **(B)**. DHT, dihydrotanshinone I; MDA, malondialdehyde; GSH, glutathione; SOD, superoxide dismutase; WT, wild type; ApoE^-/-^, apolipoprotein E-deficient.](fphar-07-00418-g008){#F8}

DHT Inhibited NOX4, NF-κB and LOX-1 Expression in ApoE^-/-^ Mice
----------------------------------------------------------------

Immunohistochemistry showed that LOX-1 was expressed at low level in aorta of WT mice but significantly increased in ApoE^-/-^ mice, which was dramatically decreased in DHT treated mice (**Figure [8A](#F8){ref-type="fig"}**). LOX-1 was mainly expressed on the endothelial cells, which was further confirmed by immunofluorescence (**Figure [8B](#F8){ref-type="fig"}**). Furthermore, immunohistochemistry analysis of aortic sinus showed that the expression of NOX4 and phosphorylated NF-κB p65 were remarkably increased in ApoE^-/-^ mice, which were significantly inhibited by DHT as well (**Figures [8F,G](#F8){ref-type="fig"}**).

Discussion
==========

Herb extracts and single compounds from *Salvia miltiorrhiza*, *Curcuma longa*, *Rheum undulatum*, and *Panax notoginseng*, have been reported to regulate multiple targets that involved in the initiation and progress of atherosclerosis ([@B37]; [@B12]; [@B50]). Here, we showed that DHT isolated from *Salvia miltiorrhiza* Bunge significantly attenuated atherosclerosis through regulating LOX-1 expression both *in vivo* and *in vitro*. The main findings of this study are: (1). DHT inhibited LPS-induced LOX-1 expression through TLR4/NOX4/NF-κB pathway in endothelial cells. (2). DHT benefited atherosclerosis by inhibiting LOX-1-mediated ox-LDL endocytosis and monocyte-endothelial cells adhesion in endothelial cells. (3). DHT attenuated atherosclerosis in ApoE^-/-^ mice through regulating LOX-1 expression.

Our previous study demonstrated that LPS induced LOX-1 expression in a TLR4/MyD88-dependent manner ([@B53]). Here, we found that LPS-induced expression of TLR4 and MyD88 was dramatically inhibited by DHT. However, DHT showed no effect on TLR2 expression. Furthermore, silencing of TLR4 and MyD88 significantly reversed LPS-induced LOX-1 expression. Thus, DHT might inhibit LPS-induced LOX-1 expression in a TLR4/MyD88 manner.

TLR4/MyD88 functions as the upstream of ROS ([@B51]). Cryptotanshinone, an analog of DHT, has been reported to inhibit ox-LDL- or LPS- induced endothelial ROS formation ([@B7]; [@B53]). In present study, DHT significantly inhibited LPS-induced ROS production in endothelial cells. Further investigation showed that DHT inhibited both LPS-induced $O_{2}^{\bullet-}$ and H~2~O~2~ production but has no effect on DPPH free radical. Thus suggested that DHT may not be a ROS scavenger. Since LPS-induced ROS production was potentially inhibited by NDAPH oxidase inhibitor DPI but not by LOX inhibitor NDGA, XO inhibitor ALL, mitochondria respiratory electron-transport chain inhibitors AA, TIFA and Rot, it suggested that NADPH oxidase was the main source of ROS in response to LPS. Among the 7 NADPH oxidase isoforms NOX4 was identified as the main contributor for LPS-induced ROS in HUVECs ([@B30]; [@B34]; [@B53]). In our study, DHT suppressed LPS-induced NOX4 expression and membrane translocation. Previous studies showed that activated TLR4/MyD88 upregulated NOX4 expression in LPS-activated cells and lead to atherosclerosis ([@B35]; [@B36]). Consistent with these findings, here we found that silence TLR4 decreased NOX4 expression in response to LPS in endothelial cells (data not shown). Furthermore, DHT inhibited LPS induced p22phox, an important NOX4 adaptor for NOX4 activation ([@B15]), expression. In addition, silence NOX4 inhibited LPS-induced LOX-1 expression. Collectively, these results suggested that DHT inhibited LPS-induced LOX-1 expression mediated by NOX4-dependent ROS.

The transcription factor NF-κB plays an essential role in regulating of various inflammatory cytokines secretion mediated by the intracellular ROS levels ([@B43]). Increased nuclear translocation of NF-κB p65 by LPS was inhibited by DHT and NOX4 siRNA. Increased LOX-1 expression was suppressed by PDTC, a NF-κB inhibitor. Thus, NOX4 mediated the downregulation of LOX-1 expression by DHT through NF-κB.

Ox-LDL uptake and monocyte-endothelial cells adhesion play important roles in promoting atherosclerosis ([@B31]; [@B11]). Binding and endocytosis of ox-LDL is considered the primary function of LOX-1 in endothelial cells ([@B39]) and macrophages ([@B23]). LOX-1 also act as an important adhesion molecule leading monocyte-endothelial cell adhesion ([@B17]; [@B1]). LPS-induced ox-LDL uptake and THP-1 cells adhesion were inhibited by anti-LOX-1 antibody suggesting the key roles of LOX-1. The inhibitory effect of NOX4 siRNA, PDTC, and DHT provide evidence that DHT inhibited ox-LDL uptake and monocyte adhesion by downregulating LOX-1.

To further confirm the anti-atherosclerotic effect of DHT, a high fat diet induced atherosclerosis was established in ApoE^-/-^ mice. Imbalance of lipid profile, formation of atherosclerotic plaque and occurrence of necrotic cores are important characteristics of atherosclerosis ([@B21]; [@B40]; [@B3]). Oral administration of DHT for 12 weeks dramatically decreased the serum levels of TG, TC, and LDL-C suggesting that DHT might benefit atherosclerosis by decreasing lipid levels. The decreased MDA and increased SOD and GSH by DHT also suggested that it also regulated oxidative stress *in vivo*. The reduction of atherosclerotic plaque sizes and the shrinkage of necrotic core areas in DHT treated ApoE^-/-^ mice provides the direct evidence for its anti-atherosclerotic effect. Furthermore, consistent with the *in vitro* results, expression of LOX-1, NOX4, and NF-κB in the aorta was also reduced by DHT. Thus, DHT showed anti-atherosclerotic effect in animal model.

Conclusion
==========

In summary, as depicted in **Figure [9](#F9){ref-type="fig"}**, this study showed that natural product DHT inhibited NF-κB mediated LOX-1 expression both *in vivo* and *in vitro* through NOX4-derived ROS generation. In view of the key roles of LOX-1 in the pathogenesis of atherosclerosis, inhibition of LOX-1 contributed to the anti-atherosclerotic effect of DHT.

![**Schematic diagram illustrating the molecular mechanisms underlying the anti-atherosclerotic effects of DHT**.](fphar-07-00418-g009){#F9}
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